Abstract
Autosomal recessive (AR) coding variants are a well-known cause of rare disorders. We quantified the contribution of these variants to developmental disorders (DDs) in the largest and most ancestrally diverse sample to date, comprising 29,745 trios from the Deciphering Developmental Disorders (DDD) study and the genetic diagnostics company GeneDx, of whom 20.4% have genetically-inferred non-European ancestries. The estimated fraction of patients attributable to exome-wide AR coding variants ranged from ∼2% to ∼18% across genetically-inferred ancestry groups, and was significantly correlated with the average autozygosity (r=0.99, p=5x10-6). Established AR DD-associated (ARDD) genes explained 90% of the total AR coding burden, and this was not significantly different between probands with genetically-inferred European versus non-European ancestries. Approximately half the burden in these established genes was explained by variants not already reported as pathogenic in ClinVar. We estimated that ∼1% of undiagnosed patients in both cohorts were attributable to damaging biallelic genotypes involving missense variants in established ARDD genes, highlighting the challenge in interpreting these. By testing for gene-specific enrichment of damaging biallelic genotypes, we identified two novel ARDD genes passing Bonferroni correction, KBTBD2 (p=1x10-7) and CRELD1 (p=9x10-8). Several other novel or recently-reported candidate genes were identified at a more lenient 5% false-discovery rate, including ZDHHC16 and HECTD4. This study expands our understanding of the genetic architecture of DDs across diverse genetically-inferred ancestry groups and suggests that improving strategies for interpreting missense variants in known ARDD genes may allow us to diagnose more patients than discovering the remaining genes.
Competing Interest Statement
KM and VDU are employees of GeneDx. ZZ, KR and RT were formerly employees of GeneDx, and KR and RT are now employees of Geisinger Health System. EJG is an employee of and holds shares in Adrestia Therapeutics. MEH is a co-founder of, consultant to and holds shares in Congenica, a genetics diagnostic company.
Funding Statement
The DDD study presents independent research commissioned by the Health Innovation Challenge Fund (grant number HICF-1009-003). This study makes use of DECIPHER, which is funded by the Wellcome Trust. The full acknowledgements can be found at www.ddduk.org/access.html. We additionally thank Rachel Hobson, Erwan Delage and the Human Genetics Informatics team at Sanger for their input on the DDD study. This research was funded in whole, or in part, by the Wellcome Trust Grant 220540/Z/20/A, 'Wellcome Sanger Institute Quinquennial Review 2021-2026'. For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. DSM is supported by a Gates Cambridge Scholarship (OPP1144).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Cambridge South Research Ethics Committee (10/H0305/83) and the Republic of Ireland Research Ethics Committee (GEN/284/12) gave ethical approval for DDD The Western Institutional Review Board, Puyallup, gave ethical approval for research on the GeneDx data (WIRB 20162523)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
